2015
The effects of proton pump inhibition on patient‐reported severity of dyspepsia when receiving dual anti‐platelet therapy with clopidogrel and low‐dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial
Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL. The effects of proton pump inhibition on patient‐reported severity of dyspepsia when receiving dual anti‐platelet therapy with clopidogrel and low‐dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. Alimentary Pharmacology & Therapeutics 2015, 42: 365-374. PMID: 26032114, PMCID: PMC4494867, DOI: 10.1111/apt.13260.Peer-Reviewed Original ResearchConceptsDual anti-platelet therapyAnti-platelet therapyGastrointestinal Event TrialLow-dose aspirinNonpain symptomsEvents trialPatient-reported outcome dataPercent of patientsPatient-reported symptomsPatient-reported outcomesPatient-reported severityOmeprazole groupProphylactic omeprazoleCardiovascular safetyGastrointestinal bleedingPain intensityClinical eventsOmeprazole useClinical significanceOutcome dataAssessment QuestionnaireClopidogrelDyspepsiaTherapyPatients
2010
Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients. Alimentary Pharmacology & Therapeutics 2010, 32: 1240-1248. PMID: 20955443, DOI: 10.1111/j.1365-2036.2010.04465.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalArthritisCyclooxygenase 2 InhibitorsDiclofenacEtoricoxibFemaleGastrointestinal DiseasesHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesPyridinesRisk FactorsSulfonesTime FactorsUpper Gastrointestinal TractConceptsClinical eventsRisk factorsLow-dose aspirin useDouble-blind randomized trialsLong-term prospective studiesCox proportional hazards modelNonsteroidal anti-inflammatory drugsDiscontinuation of NSAIDsPredictors of discontinuationUpper GI eventsLow-dose aspirinPotential risk factorsProportional hazards modelAnti-inflammatory drugsAspirin useGI eventsPatient characteristicsArthritis patientsTreat analysisRandomized trialsRheumatoid arthritisProspective studyGI effectsDyspepsiaHazards model
2009
Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary‐care providers
SPIEGEL BM, FARID M, VAN OIJEN MG, LAINE L, HOWDEN CW, ESRAILIAN E. Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists and primary‐care providers. Alimentary Pharmacology & Therapeutics 2009, 29: 871-881. PMID: 19183152, PMCID: PMC2953468, DOI: 10.1111/j.1365-2036.2009.03935.x.Peer-Reviewed Original ResearchConceptsPrimary care providersProton pump inhibitorsCommunity gastroenterologistsFirst-line proton pump inhibitorsLong-term PPI useLower guideline adherencePPI useAdverse eventsGuideline adherenceDyspepsia managementPump inhibitorsPCP groupPractice guidelinesTherapeutic decisionsBest practice guidelinesDyspepsiaGastroenterologistsConfirmatory testingAdherenceVignette surveyGuidelinesMore concernBest practicesProvidersGroup
2003
Helicobacter pylori eradication does not benefit non-ulcer dyspepsia
Laine L. Helicobacter pylori eradication does not benefit non-ulcer dyspepsia. 2003, 275-281. DOI: 10.1007/978-94-017-1763-2_28.ChaptersNon-ulcer dyspepsiaH. pylori eradication therapyPylori eradication therapyEradication therapyPylori eradicationH. pylori eradication treatmentH. pylori eradicationHelicobacter pylori eradicationPylori eradication treatmentH. pylori treatmentPylori treatmentEradication treatmentTreatment successDyspepsiaHelicobacter pyloriAetiological agentSerious methodological flawsTrialsSmall benefitPotential roleSignificant differencesMethodological flawsTherapyEradicationTreatment
2001
Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.
Laine L, Schoenfeld P, Fennerty M. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Annals Of Internal Medicine 2001, 134: 361-9. PMID: 11242496, DOI: 10.7326/0003-4819-134-5-200103060-00008.Peer-Reviewed Original ResearchConceptsH. pylori eradication therapyNonulcer dyspepsiaPylori eradication therapyEradication therapyControl therapyOdds ratioH. pyloriHelicobacter pyloriDefinition of dyspepsiaDuplicate data extractionEnd of therapyH. pylori infectionAnalysis of trialsPylori infectionCombination therapyMethodologic qualityTreatment successDyspepsiaPersistent infectionReference listsTherapyPatientsStudy designPrimary investigatorPylori
2000
H. pylori therapy is not effective for treatment of non-ulcer dyspepsia: Meta-analysis of randomized controlled trials
Laine L, Schoenfeld P, Fennerty M. H. pylori therapy is not effective for treatment of non-ulcer dyspepsia: Meta-analysis of randomized controlled trials. Gastroenterology 2000, 118: a440. DOI: 10.1016/s0016-5085(00)83874-3.Peer-Reviewed Original ResearchHow to explain outcome differences in dyspepsia studies
Fennerty M, Laine L. How to explain outcome differences in dyspepsia studies. 2000, 421-425. DOI: 10.1007/978-94-011-3927-4_44.ChaptersNon-ulcer dyspepsiaPylori infectionAdequate observation periodPlacebo-controlled trialPeptic ulcer diseaseCause of symptomsH. pylori infectionHelicobacter pylori infectionClinical treatment trialsMajor aetiological factorUlcer diseaseTreatment trialsUpper abdomenAetiological factorsEarly trial resultsStudy populationOutcome differencesEpidemiological studiesH. pyloriDyspepsiaDiscordant resultsTrial resultsObservation periodSerious methodological deficienciesTrials